Literature DB >> 17502474

Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype.

Alessandra Piccini1, Gianluigi Zanusso, Roberta Borghi, Cristiana Noviello, Salvatore Monaco, Roberta Russo, Gianluca Damonte, Andrea Armirotti, Matteo Gelati, Renzo Giordano, Pamela Zambenedetti, Claudio Russo, Bernardino Ghetti, Massimo Tabaton.   

Abstract

OBJECTIVE: To report an ataxic variant of Alzheimer disease expressing a novel molecular phenotype.
DESIGN: Description of a novel phenotype associated with a presenilin 1 mutation.
SETTING: The subject was an outpatient who was diagnosed at the local referral center. PATIENT: A 28-year-old man presented with psychiatric symptoms and cerebellar signs, followed by cognitive dysfunction. Severe beta-amyloid (Abeta) deposition was accompanied by neurofibrillary tangles and cell loss in the cerebral cortex and by Purkinje cell dendrite loss in the cerebellum. A presenilin 1 gene (PSEN1) S170F mutation was detected. MAIN OUTCOME MEASURES: We analyzed the processing of Abeta precursor protein in vitro as well as the Abeta species in brain tissue.
RESULTS: The PSEN1 S170F mutation induced a 3-fold increase of both secreted Abeta(42) and Abeta(40) species and a 60% increase of secreted Abeta precursor protein in transfected cells. Soluble and insoluble fractions isolated from brain tissue showed a prevalence of N-terminally truncated Abeta species ending at both residues 40 and 42.
CONCLUSION: These findings define a new Alzheimer disease molecular phenotype and support the concept that the phenotypic variability associated with PSEN1 mutations may be dictated by the Abeta aggregates' composition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502474     DOI: 10.1001/archneur.64.5.738

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

1.  Ataxic variant of Alzheimer's disease caused by Pro117Ala PSEN1 mutation.

Authors:  M Anheim; D Hannequin; C Boulay; C Martin; D Campion; C Tranchant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12       Impact factor: 10.154

2.  Presenilin-1 mutation associated with amnesia, ataxia, and medial temporal lobe T2 signal changes.

Authors:  Tobias C Langheinrich; Charles A J Romanowski; Stephen Wharton; Marios Hadjivassiliou
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

3.  Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation.

Authors:  Miryam Carecchio; Marina Picillo; Lorella Valletta; Antonio E Elia; Tobias B Haack; Autilia Cozzolino; Annalisa Vitale; Barbara Garavaglia; Arcangela Iuso; Caterina F Bagella; Sabina Pappatà; Paolo Barone; Holger Prokisch; Luigi Romito; Valeria Tiranti
Journal:  Neurogenetics       Date:  2017-06-29       Impact factor: 2.660

4.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

Review 5.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

6.  Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.

Authors:  Jeffrey L Frost; Kevin X Le; Holger Cynis; Elizabeth Ekpo; Martin Kleinschmidt; Roberta M Palmour; Frank R Ervin; Shikha Snigdha; Carl W Cotman; Takaomi C Saido; Robert J Vassar; Peter St George-Hyslop; Tsuneya Ikezu; Stephan Schilling; Hans-Ulrich Demuth; Cynthia A Lemere
Journal:  Am J Pathol       Date:  2013-06-07       Impact factor: 4.307

7.  Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice.

Authors:  Sadim Jawhar; Oliver Wirths; Stephan Schilling; Sigrid Graubner; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-12-10       Impact factor: 5.157

8.  Mutant presenilin 1 increases the expression and activity of BACE1.

Authors:  Luca Giliberto; Roberta Borghi; Alessandra Piccini; Rosa Mangerini; Sandro Sorbi; Gabriella Cirmena; Anna Garuti; Bernardino Ghetti; Fabrizio Tagliavini; Mohamed R Mughal; Mark P Mattson; Xiongwei Zhu; Xinglong Wang; Michela Guglielmotto; Elena Tamagno; Massimo Tabaton
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.